214 related articles for article (PubMed ID: 38012418)
1. A second-generation M1-polarized CAR macrophage with antitumor efficacy.
Lei A; Yu H; Lu S; Lu H; Ding X; Tan T; Zhang H; Zhu M; Tian L; Wang X; Su S; Xue D; Zhang S; Zhao W; Chen Y; Xie W; Zhang L; Zhu Y; Zhao J; Jiang W; Church G; Chan FK; Gao Z; Zhang J
Nat Immunol; 2024 Jan; 25(1):102-116. PubMed ID: 38012418
[TBL] [Abstract][Full Text] [Related]
2. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors.
Huo Y; Zhang H; Sa L; Zheng W; He Y; Lyu H; Sun M; Zhang L; Shan L; Yang A; Wang T
J Transl Med; 2023 Mar; 21(1):225. PubMed ID: 36978075
[TBL] [Abstract][Full Text] [Related]
3. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
4. Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches.
Unver N
Clin Exp Med; 2023 Nov; 23(7):3171-3177. PubMed ID: 37278931
[TBL] [Abstract][Full Text] [Related]
5. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
6. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar.
Chen K; Liu ML; Wang JC; Fang S
Biomol Biomed; 2024 May; 24(3):465-476. PubMed ID: 37877819
[TBL] [Abstract][Full Text] [Related]
7. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer.
Shah Z; Tian L; Li Z; Jin L; Zhang J; Li Z; Barr T; Tang H; Feng M; Caligiuri MA; Yu J
Cell Stem Cell; 2024 Jun; 31(6):803-817.e6. PubMed ID: 38663406
[TBL] [Abstract][Full Text] [Related]
8. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract][Full Text] [Related]
9. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
10. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
11. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
12. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
13. Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies.
Su S; Lei A; Wang X; Lu H; Wang S; Yang Y; Li N; Zhang Y; Zhang J
Cells; 2022 May; 11(10):. PubMed ID: 35626689
[TBL] [Abstract][Full Text] [Related]
14. Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia.
Abdin SM; Paasch D; Kloos A; Oliveira MC; Jang MS; Ackermann M; Stamopoulou A; Mroch PJ; Falk CS; von Kaisenberg CS; Schambach A; Heuser M; Moritz T; Hansen G; Morgan M; Lachmann N
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38135346
[TBL] [Abstract][Full Text] [Related]
15. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
16. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
17. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
[TBL] [Abstract][Full Text] [Related]
18. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions.
Zhang L; Tian L; Dai X; Yu H; Wang J; Lei A; Zhu M; Xu J; Zhao W; Zhu Y; Sun Z; Zhang H; Hu Y; Wang Y; Xu Y; Church GM; Huang H; Weng Q; Zhang J
J Hematol Oncol; 2020 Nov; 13(1):153. PubMed ID: 33176869
[TBL] [Abstract][Full Text] [Related]
19. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
20. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T; Yu SK; Xiang Y; Lu KH; Sun M
Front Immunol; 2022; 13():936496. PubMed ID: 35903099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]